Denny Lanfear: Hi, Ash. Thanks. Thanks for the question. So if I understand you correctly, the first question is what about the autoinjector AI ease of use and so on. And second is with respect to our Humira biosimilar and so on. I would first I’ll let Paul answer both, but I would first pre-stage remarks by saying that we’re very proud of the auto injector, very streamlined, it’s an excellent auto injector. We had a lot of experience of auto injectors, because of the Humira product, which also has an excellent autoinjector. I believe it’s a two-step auto injector and then Paul, little more back story on that for us?
Paul Reider: Sure. Yes, Ash, this is – a this is state-of-the-art auto injector. There’s no buttons to it, it’s a push to skin activation. So really it’s just – it’s the patient can press it onto their body. It’s a very reliable device delivering the dose consistently and it’s fast. The whole process start to finish can take under 10 seconds, which gives again the patient a lot of control over when and where they can do it. We’ll will have training devices. But really it’s so simple to use really anybody can learn how to do it and if they don’t, when we launch our on-body device later this year, we’ll be the only brand that offers doctors and patients three different presentations to meet their unique needs. We would imagine that the auto injector will be used both in the office for nurses who prefer this over a prefilled syringe, there is no needle exposed.
So that’s a real advantage or at home. So we’re expecting usage of both settings of care. With respect to the biosimilar launch of Amgen’s product, we’re not going to comment at this time on our pricing strategy. So I think you’ll learn more about that once we are closer or right after launch, Ash.
Rosh Dias: Yes, I would just add with respect to YUSIMRY that we engaged with the market significantly last few years and what was important to folks what’s important to those. And that is robust supply citrate free pain free formulation, small needle high patient comfort, strong price supply guarantees. So we really focused there and that’s the value proposition that we’re going to bring to the market and we think we’re going to compete well with that.
Ash Verma: Thank you.
Operator: Thank you. I would now like to turn the conference back to Denny Lanfear for closing remarks. Sir?
Denny Lanfear: Thank you, operator. Thank you all for joining us on our Q4 2022 call. As you can see, Coherus continues to progress against its goals of developing our Franchise plus launching additional products to support their development. We have also been quite busy with respect to constraining our expenses and making sure the company operates very efficiently. We look forward to Q2 when we get a little more lift with the CIMERLI sales and the Q-code and we’ll be happy to chat with you all again in August when you see how things come up for Q2. Thank you.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.
End of Q&A:
Denny Lanfear: Thank you, operator.
